Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Michael T. Barrett

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5646-1530; OpenAlex author ID A5079412164; NIH RePORTER profile ID 8783320. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 2)
Trials
0
Grants
4
Labs led
1
Collaborators
55
Papers, trials and grants by year

2012: 1 paper, 1 grant · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: none · 2019: none · 2020: 1 paper, 1 grant · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 grant · 2025: 3 papers · 2026: 1 paper, 1 grant

Papers 13

  1. Corrigendum to "Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer" [… Co-author DOI 10.1016/j.redox.2026.104395↗
  2. Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.omton.2025.200937↗
  3. Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2025.103895↗
  4. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Co-author DOI 10.1093/oncolo/oyae323↗
  5. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Co-author DOI 10.1038/s41467-023-40798-6↗
  6. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot C… Co-author DOI 10.1001/jamaoncol.2019.3394↗
  7. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.209↗
  8. Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0183871↗
  9. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Last author DOI 10.21037/jgo.2017.09.05↗
  10. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Co-author DOI 10.1038/ncomms8686↗
  11. Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts. Co-author DOI 10.1016/j.molonc.2014.04.007↗
  12. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/gm526↗
  13. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. Co-author DOI 10.1371/journal.pone.0043192↗

Grants 4

  1. New Therapuetics for Pancreatic Cancer R01CA265050↗
  2. HRD-IA signatures in pancreatic ductal adenocarcinoma UH3CA238926↗
  3. HRD-IA signatures in pancreatic ductal adenocarcinoma UH2CA238926↗
  4. High Definition Clonal Analyses of Archival Pancreatic Adenocarcinoma Samples R21CA137687↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitesh J. Borad · 2 shared papers, 2 shared grants, 2012–2026 · strength 2.15
  2. Daniel D. Von Hoff · 11 shared papers, 2012–2026 · strength 1.14
  3. Martín E. Fernández-Zapico · 1 shared grant, 2026 · strength 1.00
  4. Haiyong Han · 7 shared papers, 2012–2026 · strength 0.92
  5. Erkut Hasan Borazanci · 5 shared papers, 2020–2026 · strength 0.86
  6. Gayle Jameson · 6 shared papers, 2017–2026 · strength 0.85
  7. David J. Propper · 3 shared papers, 2023–2026 · strength 0.56
  8. Ronald M. Evans · 3 shared papers, 2023–2025 · strength 0.52
  9. Ramesh K. Ramanathan · 5 shared papers, 2012–2020 · strength 0.26
  10. Bolni Marius Nagalo · 1 shared paper, 2025 · strength 0.22
  11. Khandoker Usran Ferdous · 1 shared paper, 2025 · strength 0.22
  12. Chelsae R Watters · 1 shared paper, 2025 · strength 0.22
  13. Omeed Moaven · 1 shared paper, 2025 · strength 0.22
  14. Derek Cridebring · 1 shared paper, 2025 · strength 0.20
  15. Carlos Roberto Becerra · 1 shared paper, 2025 · strength 0.20
  16. Anup Kasi · 1 shared paper, 2025 · strength 0.20
  17. Joshua D. Rabinowitz · 1 shared paper, 2025 · strength 0.20
  18. Vincent M. Chung · 1 shared paper, 2025 · strength 0.20
  19. Angela Tatiana Alistar · 1 shared paper, 2025 · strength 0.20
  20. Lisa Evers · 3 shared papers, 2014–2017 · strength 0.14
  21. Corina E. Antal · 1 shared paper, 2023 · strength 0.12
  22. Jan C. Lumibao · 1 shared paper, 2023 · strength 0.12
  23. Nicole M. Sodir · 1 shared paper, 2023 · strength 0.12
  24. Gérard I. Evan · 1 shared paper, 2023 · strength 0.12
  25. Andrew M. Lowy · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.